Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

February 9, 2018: By Jon Swedien


Net sales of Eylea (aflibercept) in the US totaled $975 million in Q4-2017, a 14 percent increase over Q4-2016 revenues of $858 million, Regeneron reported Feb. 8.

The Tarrytown, New York, company reported that net sales of Eylea for the full year were $3.7 billion, an 11 percent increase over the 2016 total.

Bayer commercializes Eylea outside the US. Its net sales of Eylea outside of the US in Q4-2017 were $637 million, a 28 percent increase over the Q4-2016 total, Regeneron said.

Net sales outside the US for the full year were more than $2.2 billion, a 19 percent increase over the 2016 total of $1.9 billion, Regeneron said.

Regeneron recognized $231 million in Q4-2017 from its share of net profit from Eylea sales outside the US, up from $165 million in Q4-2016. For the full year, Regeneron recognized $802 million, up from $649 million in 2016.

Regeneron posted $1.6 billion in revenues in Q4-2017, compared with $1.2 billion in Q4-2016, a 29 percent increase.

The company posted $5.9 billion in revenues for all of 2017, a 21 percent increase over the $4.9 billion it posted in 2016.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Grants De Novo Request for IDx-DR’s AI Diagnostic System for Diabetic Retinopathy

Allergan Launches TrueTear Intranasal Neurostimulation Device for Dry Eye

Novartis Acquires AveXis, Gene Therapy Platform for $8.7 Billion

Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

EyePoint Secures Two US Patents for DEXYCU

SightLife Surgical Rebrands as CorneaGen, Offers New Products

Omidria Earns Listing on VA Formulary, Regains CMS Pass-Through Status

Rayner Launching 600C Monofocal Aspheric IOL in US

LENSAR Laser System Receives 510(k) Clearance for Corneal Pockets, Flaps

EyeGate Completes Enrollment, Receives Milestone Payment for Phase III Study of EGP-437 in Anterior Uveitis

SAV-IOL Seeks $20M in Financing for Active Intraocular Lens Concept with Real-Time Autofocus

AGTC Completes Enrollment for Phase I/II Study of Gene Therapy for X-linked Retinoschisis

Robert Greenberg, MD, PhD, Resigns from Second Sight

US FDA Requires RegeneRx to Conduct Third Phase III Trial for Dry Eye Candidate RGN-259

Stem Cell Implant Yields Positive Results in Phase I/II Study in Dry AMD

Drug Companies Petition Supreme Court to Hear Case Challenging Eye Drop Size

Appeals Court Rules in Favor of Alcon in Suit Brought by Elenza over EAIOLs

ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

GenSight Biologics’ LHON Candidate Improves Eyesight, Fails to Outpace Sham in Phase III Trial

I-MED Pharma’s I-PEN Receives Regulatory Approval in Colombia, Argentina

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023